| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by financing activities | 22,615 | 21,818 |
| Net decrease in cash and cash equivalents | -34,873 | -43,525 |
| Cash and cash equivalents at beginning of period | 92,646 | - |
| Cash and cash equivalents at end of period | 57,773 | - |
Vera Therapeutics, Inc. (VERA)
Vera Therapeutics, Inc. (VERA)